EE05232B1 - Reguleeritud vabastamisega graanul, meetod selle valmistamiseks ning seda sisaldav mitmehikuline ravimvorm - Google Patents

Reguleeritud vabastamisega graanul, meetod selle valmistamiseks ning seda sisaldav mitmehikuline ravimvorm

Info

Publication number
EE05232B1
EE05232B1 EEP200100254A EEP200100254A EE05232B1 EE 05232 B1 EE05232 B1 EE 05232B1 EE P200100254 A EEP200100254 A EE P200100254A EE P200100254 A EEP200100254 A EE P200100254A EE 05232 B1 EE05232 B1 EE 05232B1
Authority
EE
Estonia
Prior art keywords
preparation
dosage form
controlled release
unit dosage
form containing
Prior art date
Application number
EEP200100254A
Other languages
English (en)
Estonian (et)
Inventor
Gren Torkel
Ringberg Anders
Wikberg Martin
J. Wald Randy
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20413266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05232(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/SE1999/001463 external-priority patent/WO2000012069A1/en
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of EE200100254A publication Critical patent/EE200100254A/xx
Publication of EE05232B1 publication Critical patent/EE05232B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP200100254A 1998-11-11 1999-11-11 Reguleeritud vabastamisega graanul, meetod selle valmistamiseks ning seda sisaldav mitmehikuline ravimvorm EE05232B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9803871A SE9803871D0 (sv) 1998-11-11 1998-11-11 Therapeutic method and formulation
PCT/SE1999/001463 WO2000012069A1 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
PCT/SE1999/002052 WO2000027364A1 (en) 1998-11-11 1999-11-11 New controlled release bead, a method of producing the same and multiple unit formulation comprising it

Publications (2)

Publication Number Publication Date
EE200100254A EE200100254A (et) 2002-12-16
EE05232B1 true EE05232B1 (et) 2009-12-15

Family

ID=20413266

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100254A EE05232B1 (et) 1998-11-11 1999-11-11 Reguleeritud vabastamisega graanul, meetod selle valmistamiseks ning seda sisaldav mitmehikuline ravimvorm

Country Status (40)

Country Link
US (1) US6911217B1 (pt)
EP (1) EP1128819B1 (pt)
JP (1) JP3616011B2 (pt)
KR (1) KR100467384B1 (pt)
CN (1) CN1169522C (pt)
AP (1) AP1323A (pt)
AR (1) AR027815A1 (pt)
AT (1) ATE247458T1 (pt)
AU (1) AU762410B2 (pt)
BG (1) BG65149B1 (pt)
BR (1) BRPI9915142B8 (pt)
CA (1) CA2350061C (pt)
CZ (1) CZ299582B6 (pt)
DE (1) DE69910604T2 (pt)
DK (1) DK1128819T3 (pt)
EA (1) EA005074B1 (pt)
EE (1) EE05232B1 (pt)
ES (1) ES2204193T3 (pt)
GE (1) GEP20022833B (pt)
HK (1) HK1040917B (pt)
HR (1) HRP20010333B1 (pt)
HU (1) HU226582B1 (pt)
ID (1) ID30039A (pt)
IL (1) IL142809A0 (pt)
IS (1) IS2370B (pt)
MA (1) MA25325A1 (pt)
MY (1) MY122195A (pt)
NO (1) NO331399B1 (pt)
NZ (1) NZ511430A (pt)
OA (1) OA11673A (pt)
PL (1) PL195780B1 (pt)
PT (1) PT1128819E (pt)
RS (1) RS49891B (pt)
SE (1) SE9803871D0 (pt)
SI (1) SI1128819T1 (pt)
SK (1) SK284758B6 (pt)
TW (2) TWI222879B (pt)
UA (1) UA57165C2 (pt)
WO (1) WO2000027364A1 (pt)
ZA (1) ZA200103575B (pt)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000515525A (ja) * 1996-07-19 2000-11-21 アベーグ，グンナー 尿と胃腸の疾患の治療におけるｓ（―）―トルテロジン
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
HUP0203028A3 (en) 1999-11-11 2005-07-28 Pharmacia Ab Pharmaceutical formulation containing tolterodine and its use
MXPA05002302A (es) * 2002-08-28 2005-06-08 Pharmacia Corp Composicion liquida oral de tolterodina.
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
WO2004064821A1 (en) * 2003-01-22 2004-08-05 Pfizer Health Ab Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
ES2359375T3 (es) 2003-11-04 2011-05-20 Supernus Pharmaceuticals, Inc. Formas de dosificación de dosis única diaria de trospio.
AU2004289222B2 (en) 2003-11-04 2010-01-21 Supernus Pharmaceuticals Inc. Compositions of quaternary ammonium containing bioavailability enhancers
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
EP1629834A1 (en) † 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
TW200640839A (en) * 2005-01-10 2006-12-01 Teva Pharma Process for preparing Tolterodine tartrate
WO2006130188A1 (en) 2005-05-31 2006-12-07 The Iams Company Feline probiotic bifidobacteria
DK1880001T3 (da) 2005-05-31 2011-09-12 Iams Company Feline probiotiske lactobacilli
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
PT2997953T (pt) 2006-01-18 2019-02-04 Intec Pharma Ltd Dispositivo oe entrega para ingestão oral oe um agente
LT1993559T (lt) 2006-02-03 2016-11-10 Opko Renal, Llc Vitamino d nepakankamumo ir deficito gydymas su 25-hidroksivitaminu d2 ir 25-hidroksivitaminu d3
KR100714058B1 (ko) * 2006-02-06 2007-05-02 한국유나이티드제약 주식회사 톨테로딘 엘-주석산염의 서방형 경구투여 조성물 및 이의 제조 방법
PL1842534T3 (pl) * 2006-02-24 2012-05-31 Teva Pharma Tabletki bursztynianu metoprololu o przedłużonym uwalnianiu oraz sposoby ich wytwarzania
RU2008139634A (ru) * 2006-03-21 2010-08-27 Тева Фармасьютикл Индастриес Лтд. (Il) Фармацевтическая композиция толтеродина с контролируемым высвобождением
EP1839649A1 (en) * 2006-03-31 2007-10-03 LEK Pharmaceuticals D.D. Coated formulations for tolterodine
US9561188B2 (en) * 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
US20070248670A1 (en) * 2006-04-21 2007-10-25 Van Den Heuvel Dennie J M Tolterodine beads
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
EP2026766A1 (en) 2006-05-17 2009-02-25 Synthon B.V. Tablet composition with a prolonged release of tamsulosin
CA2655499C (en) 2006-06-21 2015-10-27 Proventiv Therapeutics, Llc Method of treating and preventing secondary hyperparathyroidism_with vitamin d repletion and vitamin d replacemnt therapies
JP2008007458A (ja) * 2006-06-29 2008-01-17 Freunt Ind Co Ltd レイヤリング用核粒子とその製造方法
MX2009005478A (es) 2006-11-27 2009-08-12 Lundbeck & Co As H Derivados de heteroarilamida.
JP5799299B2 (ja) 2007-02-01 2015-10-21 ザ・アイムス・カンパニーＴｈｅ Ｉａｍｓ Ｃｏｍｐａｎｙ ブドウ糖代謝拮抗物質、アボカド又はアボカド抽出物を使用する、哺乳動物における炎症及びストレスの低下方法
EP3335712A1 (en) 2007-04-25 2018-06-20 Opko Renal, LLC Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
US11752158B2 (en) 2007-04-25 2023-09-12 Eirgen Pharma Ltd. Method of treating vitamin D insufficiency and deficiency
JP5501956B2 (ja) 2007-04-25 2014-05-28 シトクロマ インコーポレイテッド ビタミンｄ化合物およびワックス状担体を含有する制御放出性経口組成物
US20090017111A1 (en) * 2007-07-03 2009-01-15 Van Den Heuvel Dennie J M Tolterodine bead
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
CA2696341C (en) 2007-08-13 2016-05-17 Abuse Deterrent Pharmaceutical Llc Abuse resistant drugs, method of use and method of making
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
CA2629099A1 (en) * 2008-04-01 2009-10-01 Pharmascience Inc. Novel oral controlled release pharmaceutical formulations
ES2954932T3 (es) 2008-04-02 2023-11-27 Eirgen Pharma Ltd Métodos, composiciones, usos y kits útiles para la deficiencia de vitamina D y trastornos relacionados
WO2009140557A2 (en) * 2008-05-14 2009-11-19 Capricorn Pharma, Inc. Modified release tolterodine formulations
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US8465770B2 (en) 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
EP2459180A1 (en) * 2009-07-31 2012-06-06 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
WO2011061616A2 (en) 2009-11-23 2011-05-26 Micro Labs Limited Extended release compositions containing tolterodine and process for preparing the same
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
TWI498132B (zh) 2010-03-29 2015-09-01 Ferring Bv 快速溶解之藥學組成物（二）
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
PT2552484T (pt) 2010-03-29 2020-04-03 Opko Ireland Global Holdings Ltd Métodos e composições para redução dos níveis de parafróides
US8748433B2 (en) 2010-04-30 2014-06-10 Merck Sharp & Dohme Corp. β3 adrenergic receptor agonists
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120289560A1 (en) * 2011-05-10 2012-11-15 Theravida, Inc. Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
GR1007628B (el) 2011-07-27 2012-06-29 Φαρματεν Αβεε, Φαρμακευτικο σκευασμα περιεχον εναν αντιμουσκαρινικο παραγοντα και μεθοδος για την παρασκευη αυτου
BR112014005134A2 (pt) 2011-09-16 2017-04-18 Ferring Bv composição farmacêutica de dissolução rápida
BR112014007753B1 (pt) * 2011-09-30 2021-07-06 Astellas Pharma Inc. composição farmacêutica granular, formulação e método para produção
AU2013289403B2 (en) 2012-07-12 2017-05-11 Ferring B.V. Diclofenac formulations
WO2014047477A2 (en) * 2012-09-20 2014-03-27 Sks Ocular, Llc Multilayer biodegradable microparticles for sustained release of therapeutic agents
TW201422254A (zh) * 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
US20150306170A1 (en) * 2012-11-21 2015-10-29 Ferring B.V. Composition for immediate and extended release
NZ629598A (en) * 2013-03-13 2016-10-28 Advanced Bionutrition Corp Stable bioactive substances and methods of making
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
CA2907428A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
AU2014246617A1 (en) 2013-12-23 2015-07-09 Sun Pharmaceutical Industries Limited Multi-layered, multiple unit pharmaceutical compositions
CA2957240A1 (en) 2014-08-07 2016-02-11 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin d
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
CA3018328A1 (en) * 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
EP3431107A4 (en) * 2016-02-23 2019-11-13 Nipro Corporation PARTICULARS OF A PHARMACEUTICAL COMPOSITION AND MOUTH-DISTURBING PREPARATION THEREOF
KR20230054752A (ko) 2016-03-28 2023-04-25 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1144911B (it) * 1981-03-19 1986-10-29 Pharmatec Spa Composizione farmaceutica a rilascio controllato contenente ibuprofen
JPH07107450A (ja) 1993-10-08 1995-04-21 Hitachi Ltd 情報通信装置
JP3453186B2 (ja) 1994-04-14 2003-10-06 共和薬品工業株式会社 徐放性マイクロカプセルおよびその製造方法
SE9402422D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
US5645858A (en) * 1994-10-06 1997-07-08 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
JP2000515525A (ja) 1996-07-19 2000-11-21 アベーグ，グンナー 尿と胃腸の疾患の治療におけるｓ（―）―トルテロジン
US6312728B1 (en) * 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation

Also Published As

Publication number Publication date
DE69910604D1 (de) 2003-09-25
IS2370B (is) 2008-06-15
SK284758B6 (sk) 2005-11-03
AP2001002166A0 (en) 2001-06-30
IS5936A (is) 2001-05-09
PL195780B1 (pl) 2007-10-31
SE9803871D0 (sv) 1998-11-11
EP1128819A1 (en) 2001-09-05
CA2350061A1 (en) 2000-05-18
MA25325A1 (fr) 2001-12-31
NO331399B1 (no) 2011-12-19
NO20012314L (no) 2001-07-09
CZ299582B6 (cs) 2008-09-10
JP2003517446A (ja) 2003-05-27
BG65149B1 (bg) 2007-04-30
BRPI9915142B8 (pt) 2021-05-25
HK1040917B (zh) 2005-05-27
AU1436600A (en) 2000-05-29
HUP0105038A2 (en) 2002-06-29
ID30039A (id) 2001-11-01
PL348612A1 (en) 2002-06-03
GEP20022833B (en) 2002-11-25
US6911217B1 (en) 2005-06-28
HU226582B1 (en) 2009-04-28
UA57165C2 (uk) 2003-06-16
CA2350061C (en) 2005-05-17
AU762410B2 (en) 2003-06-26
BG105582A (en) 2001-12-29
SI1128819T1 (en) 2003-12-31
KR100467384B1 (ko) 2005-01-24
AR027815A1 (es) 2003-04-16
CN1326339A (zh) 2001-12-12
TWI267385B (en) 2006-12-01
EE200100254A (et) 2002-12-16
DE69910604T2 (de) 2004-06-24
HUP0105038A3 (en) 2006-07-28
HRP20010333B1 (en) 2004-10-31
BR9915142A (pt) 2001-08-07
WO2000027364A1 (en) 2000-05-18
ES2204193T3 (es) 2004-04-16
TWI222879B (en) 2004-11-01
CZ20011627A3 (cs) 2001-10-17
KR20010075695A (ko) 2001-08-09
CN1169522C (zh) 2004-10-06
YU33101A (sh) 2003-10-31
OA11673A (en) 2005-01-12
MY122195A (en) 2006-03-31
DK1128819T3 (da) 2003-12-01
HRP20010333A2 (en) 2003-04-30
JP3616011B2 (ja) 2005-02-02
EA005074B1 (ru) 2004-10-28
SK6252001A3 (en) 2002-01-07
NZ511430A (en) 2003-05-30
EA200100538A1 (ru) 2001-10-22
PT1128819E (pt) 2003-12-31
EP1128819B1 (en) 2003-08-20
RS49891B (sr) 2008-08-07
ZA200103575B (en) 2002-05-03
AP1323A (en) 2004-11-05
NO20012314D0 (no) 2001-05-10
HK1040917A1 (en) 2002-06-28
ATE247458T1 (de) 2003-09-15
IL142809A0 (en) 2002-03-10
BRPI9915142B1 (pt) 2015-08-25

Similar Documents

Publication Publication Date Title
EE05232B1 (et) Reguleeritud vabastamisega graanul, meetod selle valmistamiseks ning seda sisaldav mitmehikuline ravimvorm
EE05214B1 (et) Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
EE200100319A (et) Reguleeritud vabanemisega galantamiinipreparaat, meetod selle valmistamiseks, seda sisaldav doseerimisvorm ning farmatseutiline pakend
HUP0103633A2 (hu) Szubsztituált 3-cianokinolinok mint protein tirozin kinázok inhibitorai, eljárás a vegyületek előállítására és a vegyületeket tartalmazó gyógyászati készítmények
EE03613B1 (et) Omeprasooli naatriumisool,selle valmistamise protsess,seda sisaldav ravimkoostis ja selle kasutamine seedetrakti häirete ravimiseks
HUP0300894A3 (en) Substituted beta-carbolines, process for their preparation, pharmaceutical compositions containing them and their use
IL138280A0 (en) 20-KETO-11β-ARYLSTERIODS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF
HUP0103567A3 (en) 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists, process for their preparation and pharmaceutical compositions containing the same
EE04739B1 (et) Tienüülasolüülalkoksüetaanamiinderivaadid, nende ja nende soolade valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ning vaheühend ja selle valmistamismeetod
HUP9900163A3 (en) Process for the preparation of sterol-and stanol-esters, and use thereof
EE200000482A (et) Glütsiini ülekannet pärssiva ühendi kasutamine ravimi valmistamiseks, ühend, seda sisaldav kompositsioon ning meetod ühendi ja kompositsiooni valmistamiseks
HUP0105313A3 (en) Potassium salt of (s)-omeprazole, process for its preparation and pharmaceutical composition containing the same and its use
EP1331517A4 (en) POSITIVE LIGHT-SENSITIVE RESIN COMPOSITION, PROCESS FOR THEIR MANUFACTURE AND SEMICONDUCTOR COMPONENTS
IL156662A0 (en) Oxazolidinone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same
IL136425A0 (en) Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use
HUP0102215A3 (en) Benzoylpyridazines, pharmaceutical compositions containing the same and process for their preparation
EE200100574A (et) Uued ühendid, nende valmistamise meetod ning kasutamine
IL137494A0 (en) Polypeptide compounds, process for the preparation thereof and pharmaceutical compositions containing the same
FR2791059B1 (fr) Proteine modifiee, procede de preparation de celle-ci et compositions pour une application externe contenant la proteine modifiee
HUP0203597A3 (en) Pharmaceutical compositions containing zolmitriptan, process for their preparation and their use
HK1039122A1 (zh) 取代的6-苄基-4-氧代嘧啶，其製備方法以及含該化合物的藥物組合物
EE200000767A (et) Asendatud triasolopüridasiini derivaat, selle valmistamismeetod ja kasutamine ning farmatseutiline kompositsioon
EE05168B1 (et) N-guanidinoalklamiid, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaat ning raviotstarbeline kasutamine
EE04902B1 (et) Mikrograanul, selle valmistamismeetod ja farmatseutiline preparaat
EE04855B1 (et) Hüübimistegurit pärssiv ühend, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaatning raviotstarbeline kasutamine

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231